Sarepta Therapeutics closed down about 22% on Tuesday - and the trigger was not its own data.
Novartis said its del-desiran candidate missed its Phase 3 endpoint in myotonic dystrophy, and investors read that failure across to other muscle-disease drug developers.
→ Details: https://marketchacha.com/companies/SRPT
This article is for educational and informational purposes only. It is not financial advice, investment recommendation, or a solicitation to buy or sell securities. Investing involves significant risks. I am not a SEBI-registered investment advisor. Readers should consult their own financial advisor and conduct their own research before making any investment decisions.
Comments
Join the conversation
Sign in to join the conversation.
Follow replies, add your view, and take part in the discussion.
Sign in to commentLoading comments...